I haven't followed PCK closely as it is clearly a lengthy path...

I haven't followed PCK closely as it is clearly a lengthy path to profitability, but I have always had faith in our long term future, since first investing in 2017. I'm currently getting myself updated ahead of the SPP. Lots of good recent commentary from holders above, thanks to all. I will be participating in the SPP across our 3 accounts tomorrow.

I'm pleased to read the good opinions of PD above. For those of us who had invested in RAP, what a contrast, PD vs Keating - a nice guy but with hindsight, clearly out of his depth in ability and a major mistake with the strategy of going gung-ho to FDA without real world validation of ResApp's efficacy. I am reasonably ok with the patented PCK slow rate of implemented uptake, given the high retention rates plus because as far as I know, it has no significant competitors. And December quarter growth has been the largest to date.

One thing that I was not aware of, and really impressed me when reading the presentation of 31 October 2023, is the reported SCOTTISH CARE INSPECTORATE PAINCHEK - 1st PHASE OUTCOMES of the Reduction in falls by 75% in 3 months (42% over 6 months). WOW, less stress and better medication regimes is one thing, but major reduction in falls is, in my book, a huge item especially given the bone etc frailty of the elderly in care facilities - very hard for them to have good recovery from bad falls.

I'm also happy to see the top 20 shareholders essentially unchanged from annual reports of 2022 vs 2023, and remaining at about 40%.